Metropolitan Life Insurance Company (MetLife)’s Castle Biosciences CSTL Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,410	Closed	-$31.2K	–	520
2024 Q1	$31.2K	Hold	1,410	–	–	﹤0.01%	1645
2023 Q4	$30.4K	Hold	1,410	–	–	﹤0.01%	1713
2023 Q3	$23.8K	Hold	1,410	–	–	﹤0.01%	1805
2023 Q2	$19.3K	Hold	1,410	–	–	﹤0.01%	1947
2023 Q1	$32K	Hold	1,410	–	–	﹤0.01%	1633
2022 Q4	$33.2K	Hold	1,410	–	–	﹤0.01%	1732
2022 Q3	$36.8K	Hold	1,410	–	–	﹤0.01%	1663
2022 Q2	$30.9K	Hold	1,410	–	–	﹤0.01%	1797
2022 Q1	$63.3K	Sell	1,410 -4,565	-76%	-$189K	﹤0.01%	1460
2021 Q4	$256K	Hold	5,975	–	–	﹤0.01%	1844
2021 Q3	$397K	Hold	5,975	–	–	0.01%	1602
2021 Q2	$438K	Buy	5,975 +1,748	+41%	+$115K	0.01%	1601
2021 Q1	$289K	Buy	4,227 +968	+30%	+$72.8K	﹤0.01%	1768
2020 Q4	$219K	Hold	3,259	–	–	﹤0.01%	1878
2020 Q3	$168K	Hold	3,259	–	–	﹤0.01%	1894
2020 Q2	$123K	Hold	3,259	–	–	﹤0.01%	2129
2020 Q1	$97.2K	Buy	+3,259	New	+$98.3K	﹤0.01%	2045

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CSTL Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Castle Biosciences (CSTL) in Q2 2024, closing a stake of 1,410 shares — an estimated $31.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CSTL in Q1 2020 and held it in 17 quarters. The position peaked at $438K in Q2 2021. 159 funds tracked by Wall St. Rank hold CSTL as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Castle Biosciences position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,410 Castle Biosciences shares in Q2 2024, an estimated $31.2K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Castle Biosciences in Q1 2020 and held it in 17 quarters.
Metropolitan Life Insurance Company (MetLife)'s Castle Biosciences position peaked at $438K in Q2 2021.
159 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.